| Combination of | |
|---|---|
| Neostigmine | Cholinesterase inhibitor |
| Glycopyrronium bromide | Antimuscarinic agent |
| Clinical data | |
| Trade names | Prevduo |
| Other names | Neostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
Neostigmine/glycopyrronium bromide, sold under the brand namePrevduo, is afixed-dose combination medication used for the reversal of the effects ofnon-depolarizingneuromuscular blocking agents aftersurgery.[2] It containsneostigmine as the methylsulfate, acholinesterase inhibitor, andglycopyrronium bromide, anantimuscarinic agent.[2]
Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,[1] and in the United States in February 2023.[3]
Neostigmine/glycopyrronium bromide isindicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.[3]
This article incorporates text from this source, which is in thepublic domain. | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
